Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (8)

« Back to Publications

Leveraging the active conformation of LFA-1 as a potential target for hematological malignancies.

Puthenveetil A. et al, (2025), Mol Ther Methods Clin Dev, 33

Isolation and characterization of primary NK cells and the enrichment of the KIR2DL1+ population.

Sabag B. et al, (2025), Methods Cell Biol, 193, 201 - 211

Dysfunctional natural killer cells can be reprogrammed to regain anti-tumor activity.

Sabag B. et al, (2024), EMBO J, 43, 2552 - 2581

ctin Retrograde Flow Regulated by the Wiskott-Aldrich Syndrome Protein Drives the Natural Killer Cell Response.

Sabag B. et al, (2022), Cancers (Basel), 14

Inhibition of SHP-1 activity by PKC-θ regulates NK cell activation threshold and cytotoxicity.

Ben-Shmuel A. et al, (2022), Elife, 11

Modulation of intrinsic inhibitory checkpoints using nano-carriers to unleash NK cell activity.

Biber G. et al, (2022), EMBO Mol Med, 14

Targeting the actin nucleation promoting factor WASp provides a therapeutic approach for hematopoietic malignancies.

Biber G. et al, (2021), Nat Commun, 12

Metabolic reprograming of tumor-associated macrophages.

Puthenveetil A. and Dubey S., (2020), Ann Transl Med, 8